Read by QxMD icon Read

neo-adjuvant chemotherapy

Alessandro Gronchi
No abstract text is available yet for this article.
July 12, 2018: European Journal of Cancer
Hiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, Yasuhiro Okumura, Toshimi Takano, Eriko Tokunaga, Tsuyoshi Saito, Yasuaki Sagara, Kosuke Yamazaki, Yoshihiro Kawaguchi, Tecchuu Lee, Shinji Ozaki, Kazuhiko Yamagami, Naohito Yamamoto, Katsumasa Kuroi, Hirofumi Suwa, Shoichiro Ohtani, Toshikazu Ito, Shinji Yasuno, Satoshi Morita, Shinji Ohno, Masakazu Toi
Background: There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer recurrence after perioperative treatment with TZM. Aim: To clarify the outcome and safety of TZM retreatment in patients with recurrent HER2-positive breast cancer. Method: An observational study was conducted on patients who relapsed after primary systemic therapy with TZM using the central registration system...
2018: Breast Cancer: Basic and Clinical Research
M Timmermans, M A van der Aa, R I Lalisang, P O Witteveen, K K Van de Vijver, R F Kruitwagen, G S Sonke
OBJECTIVE: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to adjuvant chemotherapy (TTC) was associated with clinical outcome. METHODS: We identified all Dutch patients who received optimal or complete debulking surgery for primary EOC (FIGO IIb-IV) between 2008 and 2015 from the Netherlands Cancer Registry. TTC was divided into three groups based on the interquartile range (IQR)...
July 9, 2018: Gynecologic Oncology
Rossella Loria, Valentina Laquintana, Giulia Bon, Daniela Trisciuoglio, Roberta Frapolli, Renato Covello, Carla Azzurra Amoreo, Virginia Ferraresi, Carmine Zoccali, Mariangela Novello, Donatella Del Bufalo, Michele Milella, Roberto Biagini, Maurizio D'Incalci, Rita Falcioni
Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones...
July 6, 2018: Oncogene
Andrew Robinson, Osama Souied, A Brianne Bota, Nathalie Levasseur, Carol Stober, John Hilton, Dalia Kamel, Brian Hutton, Lisa Vandermeer, Sasha Mazzarello, Anil A Joy, Dean Fergusson, Sheryl McDiarmid, Mathew McInnes, Risa Shorr, Mark Clemons
IMPORTANCE: Systemic chemotherapy can be administered either through a peripheral vein (IV), or centrally through peripherally inserted central catheter (PICC), totally implanted vascular access devices (PORTs) or tunnelled cuffed catheters. Despite the widespread use of systemic chemotherapy in patients with breast cancer, the optimal choice of vascular access is unknown. OBJECTIVE: This systematic review evaluated complication rates and patient satisfaction with different access strategies for administering neo/adjuvant chemotherapy for breast cancer...
July 4, 2018: Breast Cancer Research and Treatment
Yasuaki Sagara, Masahiro Takada, Yasuyo Ohi, Shoichiro Ohtani, Sasagu Kurozumi, Kenichi Inoue, Yoshimasa Kosaka, Masaya Hattori, Toshinari Yamashita, Shintaro Takao, Nobuaki Sato, Hiroji Iwata, Masafumi Kurosumi, Masakazu Toi
PURPOSE: While human epidermal growth factor receptor 2 (HER2) target therapies have significantly improved the prognosis of patients with HER2-enriched breast cancer, differing clinical benefits and gene expression analyses suggest a divergent HER2 subgroup. We aimed to investigate whether the basal HER2 subtype of breast cancer has distinguished characteristics. METHODS: We performed a substudy by using data from a retrospective multi-institutional cohort of JBCRG-C03...
July 3, 2018: Breast Cancer Research and Treatment
J Wei, T Yao, Y Wang, L Li, C Pan, N Zhang
AIM: To study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification. METHODS: This study retrospectively enrolled 279 patients who underwent radical gastrectomy from January 2012 to December 2014 at our hospital and who were diagnosed with stage III GC according to the new 8th edition of the TNM classification. The patient data that were collected included age, sex, pathological parameters, survival, lymph node ratio, neo-adjuvant chemotherapy with oxaliplatin and S-1, and operation type...
July 2, 2018: Clinical & Translational Oncology
Elisa Gobbini, Matteo Giaj Levra
Early non-small cell lung cancer (NSCLC) represents 16% of all new NSCLC at diagnosis with a 5-year survival rate of about 60%. Surgical intervention and adjuvant platinum-based chemotherapy represent the cornerstone treatments, but no significant advances have been achieved since several decades in term of relapse rate reduction or survival improvement. Immunotherapy represents an appealing strategy considering the acceptable toxicity profile but, despite the awesome changing recently introduced in the locally advanced and metastatic setting, its role in early NSCLC is not clear yet...
May 2018: Journal of Thoracic Disease
Zacharia Mbaidjol Kabra, Claudia Burkhardt, Benjamin Malavallon, Chayma Bettaieb, Gang Mai, Thibaud Koessler, Sylvain Terraz, Michel Forni, Philippe Morel, Leo Bühler
Pancreatic cancer is the 10th leading cause of death worldwide. It is a very lethal and aggressive tumor, with a 5-year overall survival rate under 5 % for confirmed ductal adenocarcinoma. Even though many genes have been identified as possible treatment targets, surgery remains the only curative treatment. Imaging is essential to the initial workup and is mostly based on CT-scan and MRI studies. Resectability is based on the absence of distant metastases and arterial vasculature infiltration. 3D imaging reconstruction could add precision to the surgical evaluation...
June 13, 2018: Revue Médicale Suisse
M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, K Aalders, H Forstbauer, P Fasching, E Brain, P Vuylsteke, E Guardiola, R Lorenz, K Pantel, K Tryfonidis, W Janni, M Piccart, C Sotiriou, B Rack, J-Y Pierga
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of Circulating Tumor Cells (CTCs) in women with high risk, HER2 non-amplified, early breast cancer. Patients and Methods: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase 2 trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC per 15mL of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1:1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation...
June 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Márcio Debiasi, Carisi A Polanczyk, Patrícia Ziegelmann, Carlos Barrios, Hongyuan Cao, James J Dignam, Paul Goss, Brittany Bychkovsky, Dianne M Finkelstein, Rodrigo S Guindalini, Paulo Filho, Caroline Albuquerque, Tomás Reinert, Evandro de Azambuja, Olufunmilayo Olopade
Background: Several (neo)adjuvant treatments for patients with HER2-positive breast cancer have been compared in different randomized clinical trials. Since it is not feasible to conduct adequate pairwise comparative trials of all these therapeutic options, network meta-analysis offers an opportunity for more detailed inference for evidence-based therapy. Methods: Phase II/III randomized clinical trials comparing two or more different (neo)adjuvant treatments for HER2-positive breast cancer patients were included...
2018: Frontiers in Oncology
Marianna Christodoulou, Kimberley J Reeves, Clare Hodgson, Anthi Zeniou, Finbar Slevin, Jason Kennedy, Peter J Hoskin, Ann Henry, Ananya Choudhury
INTRODUCTION: There is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial. MATERIALS AND METHODS: Data were retrospectively analysed for patients who received GemX from two oncology centres in the UK...
June 2, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Francesco Paolo Caronia, Ettore Arrigo, Andrea Valentino Failla, Francesco Sgalambro, Giorgio Giannone, Attilio Ignazio Lo Monte, Massimo Cajozzo, Mario Santini, Alfonso Fiorelli
A 67-year-old man was referred to our attention for management of esophageal adenocarcinoma, localized at the level of the esophagogastric junction and obstructed the 1/3 of the esophageal lumen. Due to the extension of the disease (T3N1M0-Stage IIIA), the patient underwent neo-adjuvant chemo-radiation therapy and he was then scheduled for a minimally invasive surgical procedure including laparoscopic gastroplasty, uniportal thoracoscopic esophageal dissection and intrathoracic end-to-end esophago-gastric anastomosis...
April 2018: Journal of Thoracic Disease
Lauren M Quinn, Alexander C Hollis, James Hodson, Mona A Elshafie, Mike T Hallissey, John L Whiting, Ewen A Griffiths
INTRODUCTION: The utility of Circumferential Resection Margin (CRM) status in predicting prognosis in oesophageal cancer is controversial, with different definitions used by the College of American Pathologists and the Royal College of Pathologists. We aimed to determine prognostic significance of CRM involvement and evaluate which system is the best predictor of prognosis. METHODS: A cohort of 390 patients who had potentially curative oesophagectomy (- + neoadjuvant chemotherapy) were analysed...
May 17, 2018: European Journal of Surgical Oncology
Xiang Hu, Ya-Qi Li, Qing-Guo Li, Yan-Lei Ma, Jun-Jie Peng, Sanjun Cai
BACKGROUND/AIMS: Colorectal mucinous adenocarcinoma (MA) has been associated with a worse prognosis than adenocarcinoma (AD) in advanced stages. Little is known about the prognostic impact of a mucinous histotype on the early stages of colorectal cancer with negative lymph node (LN) metastasis. In contrast to the established prognostic factors such as T stage and grading, the histological subtype is not thought to contribute to the therapeutic outcome, although different subtypes can potentially represent different entities...
2018: Cellular Physiology and Biochemistry
Isabella Raccagni, Sara Belloli, Silvia Valtorta, Alessandro Stefano, Luca Presotto, Claudio Pascali, Anna Bogni, Monica Tortoreto, Nadia Zaffaroni, Maria Grazia Daidone, Giorgio Russo, Emilio Bombardieri, Rosa Maria Moresco
RATIONALE: Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response)...
2018: PloS One
Giuseppe Gullo, Naomi Walsh, David Fennelly, Reetesh Bose, Janice Walshe, Dimitrios Tryfonopoulos, Kate O'Mahony, Lisa Hammond, Nuno Silva, Deirdre McDonnell, Josephine Ballot, Cecily Quinn, Enda W McDermott, Denis Evoy, Ruth Prichard, James Geraghty, John Amstrong, John Crown
BACKGROUND: The optimal timing of (neo)adjuvant trastuzumab initiation with respect to chemotherapy and surgery remains undefined. METHODS: Retrospective analysis of a large institutional database of HER2-positive patients who received anti-HER2 therapy. We included all Stage I to III patients treated with trastuzumab with a minimum follow up of 3 years. The date of first breast biopsy was recorded as initial diagnosis. RESULTS: A total of 506 patients [adjuvant: 386 (76%)-neo-adjuvant: 120 (24%)] were included...
May 18, 2018: British Journal of Cancer
Gabriella Ferrandina, Eleonora Palluzzi, Valerio Gallotta, Maria Antonietta Gambacorta, Rosa Autorino, Luigi Carlo Turco, Gabriella Macchia, Francesco Cosentino, Benedetta Gui, Maria Vittoria Mattoli, Graziana Ronzino, Vincenzo Valentini, Giovanni Scambia
PURPOSE: The aim of this Phase II, non-randomized study was to assess activity and safety of neoadjuvant chemotherapy (NACT) before chemoradiation (CT/RT) followed by radical surgery (RS) in locally advanced cervical cancer (LACC) patients. METHODS AND MATERIALS: The primary end point was rate of pathologic complete response (pCR). FIGO Stage IB2-IVA patients were administered NACT chemotherapy (paclitaxel 80 mg/m2 , carboplatin AUC 2), for 6 weeks, followed by Intensity Modulated Radiotherapy plus simultaneous boost (total dose of 50...
July 2018: European Journal of Surgical Oncology
P P Li, B Li, Y T Wang, S H Liu, Y N Zhang, R Zhang, P Bai, X G Li, L Y Wu
Objective: To analyze the prognosis of Ⅰb2 and Ⅱa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy (NACT) and radical hysterectomy. Methods: This retrospective study included patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅰ b2 and Ⅱ a2 cervical squamous cancer without high risk factors who underwent platinum-based NACT followed by radical surgery from January 2008 to January 2015. The responses of NACT were observed and compared in their effect on postoperative pathologic risk factors...
April 25, 2018: Zhonghua Fu Chan Ke za Zhi
Jung Yoon Choi, Eun Young Cho, Yoon Ji Choi, Jeong Hyeon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Yeul Hong Kim, Kyong Hwa Park
PURPOSE: We aimed to analyze the incidence, time to occurrence, and congestive heart failure (CHF) risk factors for early breast cancer patients treated with anthracycline (AC)-based chemotherapy and/or trastuzumab (T) therapy in Korea. METHODS: We included female patients > 19 years old from the Health Insurance Review and Assessment Service database who had no prior CHF history and had been diagnosed with early breast cancer between January 2007 and October 2016...
May 8, 2018: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"